Lombard Medical, Inc (Nasdaq:EVAR), a medical device company focused on
Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAA),
exhibited its Aorfix Endovascular stent graft system at the 18th
international experts’ symposium, Critical Issues in Aortic
Endografting, in Malmö, Sweden on June 27-28, 2014.
Aorfix, which was formally launched in the US last November, is the only
AAA stent graft approved by the FDA for the treatment of patients with
aortic aneurysm neck angulations up to 90 degrees providing an
‘on-label’ EVAR treatment option for US patients with tortuous AAA
anatomy for the first time.
CEO Simon Hubbert stated, "Critical Issues in Aortic Endografting is one
of the year's most important symposia for clinicians in the EVAR field.
We were encouraged by the high level of awareness of Aorfix and its
increasing use in hospitals around the world. The global community of
physicians that now recognize there is a safe, effective and
FDA-approved solution to treating the underserved patient population
with highly angulated AAAs is clearly expanding. We are confident that
this trend will continue, underpinned by the strong support of both key
opinion leaders at academic centers and community practitioners."
Critical Issues in Aortic Endografting is a pre-eminent global forum
where world-renowned clinicians convene to discuss and debate the latest
technologies, techniques and issues in aortic endograft treatment.
Dr. John Hardman (Bath, UK) presented a paper at the symposium on
Friday, June 27 entitled “Neck angulation is not an issue – proper
device selection.” In this paper he demonstrated that with the correct
choice of stent grafts, even challenging anatomies, can have successful
EVAR outcomes. Dr. Hardman specifically cited Aorfix as the stent graft
of choice when presented with challenging AAA anatomies.
Dr. Nilo Mosquera (Ourense, Spain) also presented his experiences and
results with the Aorfix Endovascular stent graft. Dr. Mosquera concluded
that “Aorfix provides a safe and effective EVAR solution for patients
with challenging anatomy within the IFU indications (0-90º neck
angulations).”
About Lombard Medical, Inc.
Lombard Medical, Inc. is a medical device company focused on device
solutions for the $1.4 billion per annum abdominal aortic aneurysm
repair market. The Company’s lead product, Aorfix™, is an endovascular
stent graft which has been specifically designed to solve the problems
that exist in treating complex tortuous anatomy, which is often present
in advanced AAA disease. Lombard Medical, Inc. is based in Oxfordshire,
England with U.S. commercial headquarters in Irvine, CA and is
registered in the Cayman Islands.
FORWARD-LOOKING STATEMENTS:
This announcement may contain forward-looking statements that reflect
the Company’s current expectations regarding future events, including
the commercialization and additional regulatory clearances of the
Company’s products, the Company's liquidity and results of operations,
as well as future capital raising activities. Forward-looking statements
involve risks and uncertainties. Actual events could differ materially
from those projected herein and depend on a number of factors, including
the success of the Company’s research and development and
commercialization strategies, the uncertainties related to the
regulatory process and the acceptance of the Company’s products by
hospitals and other medical professionals and the risks, uncertainties
and other factors described under the heading “Risk Factors” in the
Company’s prospectus filed with the Securities and Exchange Commission
dated April 25, 2014. The Company undertakes no obligation to update
these statements in the future.
Copyright Business Wire 2014